Nuveen Asset Management LLC cut its stake in shares of Pulse Biosciences, Inc. (NASDAQ:PLSE - Free Report) by 50.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 56,846 shares of the company's stock after selling 58,276 shares during the period. Nuveen Asset Management LLC owned about 0.09% of Pulse Biosciences worth $990,000 as of its most recent SEC filing.
A number of other hedge funds have also added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Pulse Biosciences by 15.1% during the 4th quarter. Vanguard Group Inc. now owns 1,146,339 shares of the company's stock valued at $19,958,000 after buying an additional 150,506 shares during the last quarter. Bank of America Corp DE raised its stake in Pulse Biosciences by 0.4% during the 4th quarter. Bank of America Corp DE now owns 788,454 shares of the company's stock valued at $13,727,000 after buying an additional 2,884 shares during the last quarter. Geode Capital Management LLC raised its stake in Pulse Biosciences by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 460,768 shares of the company's stock valued at $8,024,000 after buying an additional 3,603 shares during the last quarter. Invesco Ltd. raised its stake in Pulse Biosciences by 1,956.7% during the 4th quarter. Invesco Ltd. now owns 214,490 shares of the company's stock valued at $3,734,000 after buying an additional 204,061 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its stake in Pulse Biosciences by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 149,206 shares of the company's stock valued at $2,598,000 after buying an additional 1,092 shares during the last quarter. 76.95% of the stock is currently owned by hedge funds and other institutional investors.
Pulse Biosciences Trading Up 4.8%
Shares of NASDAQ:PLSE traded up $0.78 during midday trading on Friday, hitting $17.10. The company had a trading volume of 158,354 shares, compared to its average volume of 185,917. Pulse Biosciences, Inc. has a 12-month low of $9.70 and a 12-month high of $25.00. The company has a fifty day moving average of $16.85 and a two-hundred day moving average of $18.00.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.25) EPS for the quarter.
Wall Street Analyst Weigh In
Separately, Wall Street Zen upgraded shares of Pulse Biosciences to a "sell" rating in a research note on Monday, March 31st.
View Our Latest Research Report on PLSE
About Pulse Biosciences
(
Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Stories
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
